GLIOMA, MALIGNANT
Clinical trials for GLIOMA, MALIGNANT explained in plain language.
Never miss a new study
Get alerted when new GLIOMA, MALIGNANT trials appear
Sign up with your email to follow new studies for GLIOMA, MALIGNANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hard-to-treat cancers: experimental drug targets MTAP-loss tumors
Disease control Recruiting nowThis study tests a new oral drug, TNG456, in people with advanced solid tumors that have lost a gene called MTAP. The drug works by blocking a protein (PRMT5) that these tumors need to grow. The study has two parts: first, finding the safest dose of TNG456 alone or with abemacicl…
Matched conditions: GLIOMA, MALIGNANT
Phase: PHASE1, PHASE2 • Sponsor: Tango Therapeutics, Inc. • Aim: Disease control
Last updated May 16, 2026 23:38 UTC
-
Stem cells loaded with virus take on deadly brain cancer
Disease control Recruiting nowThis early-phase trial tests whether giving multiple doses of a special stem cell therapy (NSC-CRAd-S-pk7) directly into the brain is safe for people with newly diagnosed high-grade glioma. Participants receive the therapy before, during, and after standard radiation and chemothe…
Matched conditions: GLIOMA, MALIGNANT
Phase: PHASE1 • Sponsor: Northwestern University • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
New drug trial hopes to control recurrent brain tumors
Disease control Recruiting nowThis early-phase study tests an experimental drug called CUE-102 in 18 adults whose glioblastoma (a type of brain cancer) has returned after initial treatment. The main goal is to check the drug's safety and find the best dose. Participants must have a specific genetic marker (HL…
Matched conditions: GLIOMA, MALIGNANT
Phase: PHASE1 • Sponsor: David Reardon, MD • Aim: Disease control
Last updated May 01, 2026 15:58 UTC
-
New imaging test may end guesswork in childhood brain tumors
Diagnosis Recruiting nowThis study is testing whether a special PET-MRI scan using 18F-Fluciclovine can help doctors tell the difference between actual tumor growth and harmless changes that happen after treatment in children with high-grade glioma. About 30 children aged 1 to 21 with this type of brain…
Matched conditions: GLIOMA, MALIGNANT
Phase: EARLY_PHASE1 • Sponsor: Children's Hospital of Philadelphia • Aim: Diagnosis
Last updated May 16, 2026 23:48 UTC
-
Brain tumor patients may sharpen thinking with At-Home rehab program
Symptom relief Recruiting nowThis study tests a remote cognitive rehabilitation program for people with slow-growing brain tumors (grade 2 or 3 glioma). Participants will complete online exercises designed to improve memory, attention, and thinking skills. The goal is to see if this program can reduce cognit…
Matched conditions: GLIOMA, MALIGNANT
Phase: NA • Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle • Aim: Symptom relief
Last updated May 16, 2026 23:50 UTC
-
New scan could help track Kids' brain tumors without extra needles
Knowledge-focused Recruiting nowThis study is testing whether a special PET-MRI scan using a tracer called 18F-Fluciclovine can better monitor low-grade gliomas (a type of brain tumor) in children and young adults. About 30 participants will get the scan before starting treatment, then again at 3 months and 1 y…
Matched conditions: GLIOMA, MALIGNANT
Phase: EARLY_PHASE1 • Sponsor: Children's Hospital of Philadelphia • Aim: Knowledge-focused
Last updated May 14, 2026 12:06 UTC
-
New brain tumor drug put to the test in tiny trial
Knowledge-focused Recruiting nowThis early study tests an oral drug called DSP-0390 in 20 adults with IDH-mutant gliomas (a type of brain tumor) who are scheduled for surgery. Participants take the drug for about two weeks before their tumor is removed, allowing researchers to measure how much drug reaches the …
Matched conditions: GLIOMA, MALIGNANT
Phase: EARLY_PHASE1 • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated May 11, 2026 20:51 UTC